Susan G. Komen Blog

Stories about breast cancer that can inspire and inform

Blog  |  Newsroom

A New Era in MBC Care: Understanding the SERENA-6 Approval and ctDNA-Guided Treatment Switching 

The recent FDA approval stemming from the SERENA-6 clinical trial may usher in a new era in metastatic breast cancer (MBC) care. Evidence from the trial showed how a simple blood test using circulating tumor DNA (ctDNA) can help doctors guide treatment decisions for metastatic breast cancer (MBC). ctDNA testing can detect molecular changes in a blood sample instead of relying solely on imaging scans to identify cancer progression. SERENA-6 is the first large, randomized clinical trial in breast cancer to provide evidence that ctDNA findings can be used to guide treatment decisions before progression is visible on scans.  

The SERENA-6 trial recently led to the FDA approval of an oral selective estrogen receptor degrader (SERD) camizestrant in combination with a CDK4/6 inhibitor for certain patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) locally advanced or metastatic breast cancer who develop an ESR1 mutation while taking their initial treatment with an aromatase inhibitor and a CDK4/6 inhibitor. This approval reflects a shift toward using biomarkers (such as ESR1 mutation) to help guide treatment decisions earlier than ever before. 

For people living with HR+/HER2- MBC, hormone therapies are a standard treatment. However, many tumors develop resistance to these therapies over time. One common cause of resistance is the development of ESR1 mutations, which can emerge during treatment and make tumors less responsive to certain hormone therapies.  

The SERENA-6 trial explored whether treatment decisions could be informed by emerging ESR1 mutations detected through ctDNA testing. The trial found that median progression-free survival was 16.0 months for participants who switched to camizestrant while continuing a CDK4/6 inhibitor, compared with 9.2 months for those who continued their original treatment.  

The positive findings ultimately led to FDA approval of camizestrant and sparked huge discussions across the breast cancer community about the future of ctDNA-guided treatment decision-making in MBC.  

Why Is SERENA-6 Different? 

For decades, treatment changes in MBC have been guided by radiographic progression, meaning scans show evidence that the cancer is growing or spreading. In other words, doctors usually wait until they see that treatment is no longer working before considering switching to another treatment.  

SERENA-6 challenged this approach and evaluated a different strategy by using ctDNA testing to look for emerging ESR1 mutations in the blood that can develop as tumors adapt to hormone therapy. This trial wanted to see whether acting on those molecular changes earlier could benefit patients rather than waiting for progression to become visible on scans. 

For many experts and advocates, this distinction is the most important part of the trial. Victoria Goldberg, a member of Komen’s MBC Steering Committee, described SERENA-6 as “a paradigm change in how we look at progression.” While camizestrant belongs to a drug class already familiar to many patients and doctors, the use of molecular information to inform treatment decisions before visible cancer progression is a new approach.  

Goldberg also explained a simple way to understand ESR1 mutations: “The cancer is becoming smarter and finding a way to avoid treatment.” Detecting those changes earlier may allow doctors to act on signs of emerging treatment resistance before cancer progression is detected on imaging scans.  

Why the MBC Community Is Paying Attention 

The FDA approval came as a surprise to many patient advocates, particularly following concerns raised during the regulatory review process about whether the available data were sufficient to support earlier treatment switching. Many weren’t sure whether the FDA would ultimately approve this approach. For many people living with MBC, one of the most important parts of SERENA-6 is the possibility of knowing when treatment is becoming less effective earlier rather than waiting for months for changes to appear on scans. “This is the new paradigm. This is the way it’s going to be,” Goldberg said. 

At the same time, the research and advocacy community has important questions. The trial showed benefits associated with early treatment switching, but the community continues to wonder when the best time is to switch treatment after an ESR1 mutation is detected and how ctDNA results should be weighed alongside scan results. Another key question is whether earlier intervention will improve overall survival, as those data are not yet mature. Even with those unanswered questions, many in the MBC community see value in having more information sooner rather than later. 

Another part of the trial that resonated with many patients was its impact on quality of life. While efficacy outcomes are often a primary focus, quality of life remains a critical consideration for people living with MBC. This trial showed participants who switched to camizestrant reported improved quality of life, in addition to delaying cancer progression. This is a huge deal for people living with MBC as managing side effects and maintaining daily functioning are as important as achieving clinical benefits.  

What Patients Should Know About ctDNA Testing 

As ctDNA testing is becoming more integrated into some aspects of breast cancer care, it is critical that people understand the opportunities and limitations of these tools, which require patient education and self-advocacy. Patients may want to discuss biomarker testing and liquid biopsies with their health care team, including if testing may be appropriate and how results could influence treatment decisions. CtDNA testing does not replace imaging scans or other clinical assessments used to monitor cancer. Understanding the purpose of ctDNA testing can help patients participate more actively in conversations about their care. As Goldberg noted, “It’s very important for a person to know what to ask for and understand why they need to ask for it.” 

“It’s very important for a person to know what to ask for and understand why they need to ask for it.” 

However, access remains an important consideration. While some cancer centers incorporate biomarker testing into care, awareness and use of these tools may vary across different clinic settings. Goldberg emphasized that education will be critical for both patients and providers about ctDNA-guided approaches in breast cancer care.  

What’s Next? 

The SERENA-6 approval is more than the addition of another treatment option for HR+/HER2- MBC. It highlights the growing role of ctDNA testing and raises the possibility that treatment decisions may be guided by molecular changes happening long before they can be seen on scans.  

While questions remain about how best to implement this approach in routine care, many experts and advocates view SERENA-6 as an important step toward more personalized treatment strategies. Further research, education and access to testing will be essential as doctors and patients work together to determine how ctDNA-guided care can be used to improve outcomes for people living with MBC. 

Check out our What’s New Page to learn about the most recent developments in breast cancer research and clinical trial results.  

Go to our Clinical Trials Page to learn more about clinical trials, find a trial and connect with a patient navigator who can answer your questions.